These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1911 related articles for article (PubMed ID: 30979735)
1. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
2. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204 [TBL] [Abstract][Full Text] [Related]
3. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226 [TBL] [Abstract][Full Text] [Related]
4. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
5. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655 [TBL] [Abstract][Full Text] [Related]
6. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536 [TBL] [Abstract][Full Text] [Related]
7. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593 [TBL] [Abstract][Full Text] [Related]
8. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709 [TBL] [Abstract][Full Text] [Related]
9. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926 [TBL] [Abstract][Full Text] [Related]
10. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization. Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N Front Immunol; 2024; 15():1389018. PubMed ID: 38720898 [TBL] [Abstract][Full Text] [Related]
11. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199 [TBL] [Abstract][Full Text] [Related]
12. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195 [TBL] [Abstract][Full Text] [Related]
13. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371 [TBL] [Abstract][Full Text] [Related]
14. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710 [TBL] [Abstract][Full Text] [Related]
15. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568 [TBL] [Abstract][Full Text] [Related]
16. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139 [TBL] [Abstract][Full Text] [Related]
17. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy. Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890 [TBL] [Abstract][Full Text] [Related]